Last week, the Federal Circuit handed down a pair of non-precedential decisions affirming the Patent Trial and Appeal Board (PTAB) in inter partes review (IPR) proceedings. This post.
On May 18, 2023, the Supreme Court in Amgen Inc. v. Sanofi unanimously affirmed the Federal Circuit’s holding that U.S. Patent Nos. 8,829,165 and 8,859,741 did not enable certain.
It has been a while since the Federal Circuit weighed in on the patent eligibility of so-called "natural product" claims. While the finding of non-eligibility in ChromaDex, Inc. v. Elysium.
Federal Circuit weighed in on patent eligibility of natural product claims. Non-eligibility in ChromaDex, Inc. v. Elysium Health, Inc. is not surprising, court chose to distinguish Natural Alternatives instead of characterizing decision as based on a unique procedural posture.
It has been a while since the Federal Circuit weighed in on the patent eligibility of so-called “natural product” claims. While the finding of non-eligibility in ChromaDex, Inc. v..